{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:48:22Z","timestamp":1793947702634,"version":"4.8.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005242","name":"Heed Ophthalmic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To compare the rates of intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) after injection of intravitreal (IVT) antivascular endothelial growth factor drugs.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This study included all phase 3 randomized clinical trials of patients with nAMD treated with ranibizumab, aflibercept, brolucizumab, abicipar pegol, or faricimab. The outcomes assessed were the incidence of IOI, retinal artery occlusion (RAO), retinal vasculitis and choroiditis, endophthalmitis, and serious systemic adverse events (AEs) as well as the change in visual acuity (VA) (Early Treatment Diabetic Retinopathy Study letters) and in central retinal thickness (CRT).\n                    <jats:bold>Results:<\/jats:bold>\n                    Abicipar pegol was associated with a higher incidence of IOI than aflibercept, ranibizumab, faricimab, and sham injections, while brolucizumab was associated with a higher rate of IOI than aflibercept, faricimab, and sham injections. Abicipar pegol was also associated with a higher rate of endophthalmitis than aflibercept. Significantly more retinal vasculitis and choroiditis was seen with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively, and RAOs occurred more frequently with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively. There were no differences in the change in VA among the drugs. Treatment with brolucizumab resulted in a greater change in CRT than with abicipar pegol, aflibercept, ranibizumab, and faricimab, while treatment with faricimab resulted in a greater change in CRT than aflibercept and ranibizumab. Faricimab was associated with fewer serious systemic AEs than aflibercept.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Abicipar pegol and brolucizumab were associated with a higher incidence of ocular AEs in phase 3 randomized controlled trials. The potential benefits of these drugs should be weighed against the AEs.\n                  <\/jats:p>","DOI":"10.1177\/24741264251332515","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T12:44:46Z","timestamp":1745239486000},"page":"406-415","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-1373","authenticated-orcid":false,"given":"Marta","family":"Stevanovic","sequence":"first","affiliation":[{"name":"Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Koulisis","sequence":"additional","affiliation":[{"name":"USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"},{"name":"Retina Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros N.","family":"Moysidis","sequence":"additional","affiliation":[{"name":"Retina Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Burkemper","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Toy","sequence":"additional","affiliation":[{"name":"USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsing A.","family":"Rao","sequence":"additional","affiliation":[{"name":"USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Eliott","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Humayun","sequence":"additional","affiliation":[{"name":"USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"},{"name":"USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.1971"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.012"},{"key":"e_1_3_3_4_2","unstructured":"Williams GA. IVT injections: health policy implications. Published 2014. Accessed August 6 2023. https:\/\/www.reviewofophthalmology.com\/article\/ivt-injections-health-policy-implications"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100680"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.05.012"},{"key":"e_1_3_3_10_2","unstructured":"Allergan plc and Molecular Partners. Allergan and Molecular Partners announce topline safety results from MAPLE study of abicipar pegol. Published 2019. Accessed August 6 2023. https:\/\/www.molecularpartners.com\/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol\/"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201810204"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019002108"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.017"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.035"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.03.057"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"e_1_3_3_24_2","volume-title":"Presented at: American Academy of Ophthalmology Annual Meeting","author":"Pierce IA","unstructured":"Pierce IA, Figueroa MS, Kotecha A, et al. Faricimab in neovascular age-related macular degeneration: year 2 patient case profiles from the phase 3 TENAYA and LUCERNE trials. Presented at: American Academy of Ophthalmology Annual Meeting; September 30-October 3, 2022; Chicago, IL."},{"key":"e_1_3_3_25_2","volume-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias S","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE); 2014. NICE Decision Support Unit Technical Support Documents."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2018-102911"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)78239-X"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.5.613"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.199"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000154"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0636-3"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S405994"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.072876"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.031"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26333"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100989"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000513048"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5068"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4835(91)90225-4"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3511-y"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304019"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2005.00899.x"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00639.x"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.246"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5241"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.03.544"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.6.3187"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251332515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251332515","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251332515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:26:01Z","timestamp":1790695561000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251332515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/24741264251332515"],"URL":"https:\/\/doi.org\/10.1177\/24741264251332515","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}